BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302252% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines External R&D by Year
External R&D — BEQALZI / Sonrotoclax (BGB-11417, BCL2 Inhibitor) ($M) ($M)
BeOne Medicines External R&D: $177M in FY2025, up 76.8% from a year earlier.
Latest, FY2025
177
Period ended Dec 31, 2025
Change on a year earlier
+76.8%
99.9 in FY2024
History
6 years
Since FY2020
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Sonrotoclax (BCL2 Inhibitor) | 176,716 | 99,939”
Reported in Form 8-K EX-99.1 SSE STAR Market Annual Reports (688235.SS).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | External R&D — BEQALZI / Sonrotoclax (BGB-11417, BCL2 Inhibitor) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 177 | +76.8% | 8-K STAR Report (2026-04-14, 0001651308-26-000008) ↗ |
| FY2024 | Dec 31, 2024 | 99.9 | +90.2% | 8-K STAR Report (2026-04-14, 0001651308-26-000008) ↗ |
| FY2023 | Dec 31, 2023 | 52.5 | +134.8% | 8-K STAR Report (2025-04-28, 0001651308-25-000057) ↗ |
| FY2022 | Dec 31, 2022 | 22.4 | +103.8% | 8-K STAR Report (2024-04-26, 0001651308-24-000043) ↗ |
| FY2021 | Dec 31, 2021 | 11.0 | +121.8% | 8-K STAR Report (2023-04-25, 0001651308-23-000061) ↗ |
| FY2020 | Dec 31, 2020 | 4.95 | – | 8-K STAR Report (2022-04-28, 0001651308-22-000058) ↗ |
Cite this data
StockData. (2026). BeOne Medicines External R&D ($M), annual FY2020–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-mol-sonrotoclax
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.